SAFETY AND EFFICACY

[1]  P. Mozden,et al.  Reduced estriol excretion in patients with breast cancer prior to endocrine therapy. , 1966, JAMA.

[2]  C. Nappi,et al.  Salmon calcitonin plus intravaginal estriol: an effective treatment for the menopause. , 1996, Maturitas.

[3]  G. A. Bailey,et al.  Methotrexate in the treatment of corticosteroid-dependent asthma. A double-blind crossover study. , 1988, The New England journal of medicine.

[4]  H. Lemon.  Antimammary carcinogenic activity of 17‐alpha‐ethinyl estriol , 1987, Cancer.

[5]  Postmenopausal hormone therapy and mortality. , 1997 .

[6]  C. Longcope,et al.  Estriol production rates and breast cancer. , 1978, The Journal of clinical endocrinology and metabolism.

[7]  M. Fukunaga,et al.  Effect of Estriol on Bone Loss in Postmenopausal Japanese Women: A Multicenter Prospective Open Study , 1996, The journal of obstetrics and gynaecology research.

[8]  C. Longcope.  Estriol production and metabolism in normal women. , 1984, Journal of steroid biochemistry.

[9]  R. Punnonen,et al.  The effect of oral estriol succinate therapy on the endometrial morphology in postmenopausal women: the significance of fractionation of the dose. , 1983, European journal of obstetrics, gynecology, and reproductive biology.

[10]  M. Guttadauria,et al.  Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. , 1985, Arthritis and rheumatism.

[11]  G A Colditz,et al.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. , 1995, The New England journal of medicine.

[12]  A. H. Follingstad.  Estriol, the forgotten estrogen? , 1978, JAMA.

[13]  J. L. Liu,et al.  Prospective double-blind study of CEE3 in peri- and postmenopausal women: effects on bone loss and lipoprotein lipids. , 1992, Chinese medical journal.

[14]  G. Alarcón,et al.  Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. , 1989, Arthritis and rheumatism.

[15]  C. Bieglmayer,et al.  NEW TREATMENT OF ATROPHIC ACNE SCARS BY IONTOPHORESIS WITH ESTRIOL AND TRETINOIN , 1995, International journal of dermatology.

[16]  P. Siiteri,et al.  Source of Estrogen Production in Postmenopausal Women , 1973 .

[17]  D. Thompson,et al.  Association of exogenous estrogen and endometrial carcinoma. , 1975, The New England journal of medicine.

[18]  R. Lindsay,et al.  Bone loss during oestriol therapy in postmenopausal women. , 1979, Maturitas.

[19]  S. Thacker,et al.  A Meta-analysis of the Effect of Estrogen Replacement Therapy on the Risk of Breast Cancer , 1991 .

[20]  J. Thijssen,et al.  Biochemical and histological effects of vaginal estriol and estradiol applications on the endometrium, myometrium and vagina of postmenopausal women. , 1997, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[21]  M. Lippman,et al.  Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. , 1977, Cancer research.

[22]  H. Ziel,et al.  Increased risk of endometrial carcinoma among users of conjugated estrogens. , 1975, The New England journal of medicine.

[23]  S. Sasson,et al.  Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol. , 1997, Molecular endocrinology.

[24]  G. Vooijs,et al.  Review of the endometrial safety during intravaginal treatment with estriol. , 1995, European journal of obstetrics, gynecology, and reproductive biology.

[25]  J. H. Clark,et al.  Nuclear binding and retention of the receptor estrogen complex: relation to the agonistic and antagonistic properties of estriol. , 1977, Endocrinology.

[26]  R. Hoover,et al.  The risk of breast cancer after estrogen and estrogen-progestin replacement. , 1989, The New England journal of medicine.

[27]  T. Stankovic,et al.  Treatment of climacteric complaints with oestriol. , 1975, Arzneimittel-Forschung.

[28]  R. Lammintausta,et al.  The effect of estriol succinate therapy on plasma renin activity and urinary aldosterone in postmenopausal women. , 1978, Maturitas.

[29]  H. Ng,et al.  Efficacy and safety of estriol replacement therapy for climacteric women. , 1995, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed.

[30]  J. Davies,et al.  THE EFFECTS OF LONG‐TERM THERAPY WITH OESTRIOL UCCINATE ON THE HAEMOSTATIC MECHANISM IN OSTMENOPAUSAL WOMEN , 1978 .

[31]  L. Cardozo,et al.  Oestriol in the treatment of postmenopausal urgency: a multicentre study. , 1993, Maturitas.

[32]  W. Stamm,et al.  A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. , 1993, The New England journal of medicine.

[33]  E. Ooms,et al.  The effect of estriol on the cytology of urethra and vagina in postmenopausal women with genito-urinary symptoms. , 1993, European journal of obstetrics, gynecology, and reproductive biology.